Who
Christian Todd Nichols
SVP, Chief Commercial Officer
Company insider
Files Form 4 as: SVP, Chief Commercial Officer, Alkermes.
In numbers
- Trades disclosed
- 127
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $2.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Jun 2020
- Last trade
- 17 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 17 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $340K6,912 at $49.19 | filing |
| 17 Aug 2026filed 17 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $33K664 at $49.65 | filing |
| 17 Aug 2026filed 17 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $340K6,912 at $49.19 | filing |
| 17 Aug 2026filed 17 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $33K664 at $49.65 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $180K6,000 at $30.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —66,430 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,854 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —66,430 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,854 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $180K6,000 at $30.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —5,410 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $74K2,403 at $30.73 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,410 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,410 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —5,410 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $74K2,403 at $30.73 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,407 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $92K2,845 at $32.19 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,407 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,407 | filing |
News
Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)ALKS · themarketsdaily.com · 20 Oct 2026Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Christian Todd Nichols; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.